Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Dropless Pars Plana Vitrectomy Study
NCT05331664 · View on ClinicalTrials.gov ↗
Study Summary
To demonstrate that intraoperative use of subtenon triamcinolone acetonide at the time of surgery without postoperative eye drops is non-inferior to the regimen of postoperative eye drops following primary pars plana vitrectomy for retinal detachment.
Conditions Studied
Interventions
- DRUG Atropine 1%
- PROCEDURE Pars plana vitrectomy
- DRUG Triamcinolone Acetonide 40mg/mL
- DRUG Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin
- DRUG Prednisolone 1%
Study Locations (1)
Massachusetts
- Massachusetts Eye and Ear — Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2022-07-25 |
| Est. Completion | 2027-01-30 |
| Phase | Phase 4 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05331664
The ClinicalTrials.gov registry entry for NCT05331664 describes a study currently listed as recruiting. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts Eye and Ear Infirmary, which has 94 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Rhegmatogenous Retinal Detachment appearing as the primary indexed condition, and to 5 interventions — of which Atropine 1% is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05331664 reports 1 study location spanning 1 distinct geographic area — top geographies include Massachusetts. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05331664 about?
NCT05331664 is a clinical study titled "Dropless Pars Plana Vitrectomy Study". To demonstrate that intraoperative use of subtenon triamcinolone acetonide at the time of surgery without postoperative eye drops is non-inferior to the regimen of postoperative eye drops following primary pars plana vitrectomy for retinal detachment.
What is the current status of trial NCT05331664?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 168 participants. The study started on 2022-07-25. Estimated completion is 2027-01-30.
What conditions does trial NCT05331664 study?
This clinical trial studies the following conditions: Rhegmatogenous Retinal Detachment. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05331664?
The interventions under investigation include: Atropine 1% (DRUG), Pars plana vitrectomy (PROCEDURE), Triamcinolone Acetonide 40mg/mL (DRUG), Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin (DRUG), Prednisolone 1% (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05331664?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 94 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05331664 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.